Lentiviral vectors: optimization of packaging, transduction and gene expression
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Gene transfer vectors based on retroviruses including oncogenic retroviruses and lentiviruses provide effective means for the delivery, integration and expression of exogenous genes in mammalian cells. Lentiviral (LV) vectors provide attractive gene delivery vehicles in the context of non-dividing cells. This review summarizes the different optimized LV genetic systems that have been developed to date. In all cases, the production of LV-derived vectors consists of a genetically split gene expression design. The viral elements that are specifically required are (i). the LV packaging helper proteins consisting of at least the gag-pol genes, (ii). the LV transfer vector RNA containing the transgene expression cassette, and (iii). an heterologous glycoprotein. While the genetic requirements and performances of the two former viral elements will be treated herein, the latter element relative to the envelope pseudotyping of LV vectors will not be further described (cf. review by Cosset in this issue).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
Naldini, L., Blömer, U., Gallay, P., Ory, D., Mulligan, R., Gage, F. H., Verma, I. M., & Trono, D. (1996) · Science · doi:10.1126/science.272.5259.263 · Cited by 4,903 · cited 2×
“The majority of LV encapsidation sites require the presence in the transfer vector RNA of a minimal 5′fragment of the gag gene that contains stem loop structure(s) necessary for the cis-packaging activity [1,8,9,24,26].”
BackgroundA Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341 · cited 2×
“In the gene transfer context, all accessory proteins (vpr, vpu, vif and nef) have been omitted in the production design without any negative effect on vector recovery yield [18,19].”
BackgroundMultiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977 · cited 1×
“In the gene transfer context, all accessory proteins (vpr, vpu, vif and nef) have been omitted in the production design without any negative effect on vector recovery yield [18,19].”
BackgroundSelf-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, A., Quiroz, D., Naldini, L., & Trono, D. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9873-9880.1998 · Cited by 1,815
Development of a self-inactivating lentivirus vector
Miyoshi, H., Blömer, U., Takahashi, M., Gage, F. H., & Verma, I. M. (1998) · Journal of Virology · doi:10.1128/jvi.72.10.8150-8157.1998 · Cited by 1,196 · cited 2×
“1 [28,29,59,60], SIV [3,61] and EIAV [57] contexts.”
BackgroundThe protein CTCF is required for the enhancer blocking activity of vertebrate insulators
Bell, A. C., West, A. G., & Felsenfeld, G. (1999) · Cell · doi:10.1016/s0092-8674(00)81967-4 · Cited by 1,101
The "beta-like-globin" gene domain in human erythroid cells.
Tuan, D., Solomon, W., Li, Q., & London, I. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6384 · Cited by 601 · cited 1×
“The discovery of DNaseI hypersensitive sites (HS) far upstream of the human β-globin cluster [94,95] has improved the prospects for gene therapy for human hemoglobinopathies.”
BackgroundMay, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M. (2000) · Nature · doi:10.1038/35017565 · Cited by 567
Development of a Novel Trans-Lentiviral Vector That Affords Predictable Safety
Wu, X., Wakefield, J. K., Liu, H., Xiao, H., Kralovics, R., Prchal, J. T., & Kappes, J. C. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0095 · Cited by 137
Cited by
Production and purification of lentiviral vectors
Tiscornia, G., Singer, O., & Verma, I. M. (2006) · Nature Protocols · doi:10.1038/nprot.2006.37 · Cited by 996
Viral vectors: from virology to transgene expression
Bouard, D., Alazard‐Dany, N., & Cosset, F. (2009) · British Journal of Pharmacology · doi:10.1038/bjp.2008.349 · Cited by 360
Sinn, P. L., Sauter, S. L., & McCray, P. B. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302570 · Cited by 322
Periprostatic adipocytes act as a driving force for prostate cancer progression in obesity
Laurent, V., Guérard, A., Mazerolles, C., Le Gonidec, S., Toulet, A., Nieto, L., Zaidi, F., Majed, B., Garandeau, D., Socrier, Y., et al. (2016) · Nature Communications · doi:10.1038/ncomms10230 · Cited by 296
Production of lentiviral vectors
Merten, O.-W., Hebben, M., & Bovolenta, C. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.17 · Cited by 294
Bossaert, M., Pipier, A., Riou, J.-F., Noirot, C., Nguyên, L.-T., Serre, R.-F., Bouchez, O., Defrancq, E., Calsou, P., Britton, S., et al. (2021) · eLife · doi:10.7554/elife.65184 · Cited by 97
“Transfection of HEK-293T cells (kindly provided by Genethon, Evry, France) with pLV-tTR-KRAB-Red or pLVTHM, and preparation of high titer lentiviruses pseudotyped with VSV-G protein have been performed as previously described (Delenda, 2004).”
MethodLentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease
Marquez Loza, L. I., Yuen, E. C., & McCray, P. B. (2019) · Genes · doi:10.3390/genes10030218 · Cited by 59
“In some cases, rev genes are separated from gag-pol as a fourth component [84,85].”
Background
Metadata
- Authors
- Delenda, C.
- Venue
- The Journal of Gene Medicine
- Publisher
- Wiley
- Published
- 2004-02
- Volume
- 6
- Issue
- S1
- Pages
- S125-S138
- ISSN
- 1099-498X (ISSN-L)
- 1521-2254
- OpenAlex
- W2103088365
- Cited by
- 132
- References
- 9
- FWCI
- 5.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.